UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1248-8
Program Prior Authorization/Notification
Medication Palynziq™ (pegvaliase-pqpz)
P&T Approval Date 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 7/2023, 7/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Palynziq is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine
concentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine
concentrations greater than 600 micromol/L on existing management.
2. Coverage Criteriaa:
A. Initial Authorization
1. Palynziq will be approved based on all of the following criteria:
a. Diagnosis of phenylketonuria (PKU)
-AND-
b. Patient has a blood phenylalanine concentration greater than 600 micromol/L
-AND-
c. Patient is actively on a phenylalanine-restricted diet
-AND-
d. Patient is not receiving Palynziq in combination with sapropterin dihydrochloride
Authorization will be issued for 12 months.
B. Reauthorization
1. Palynziq will be approved based on all of the following criteria:
a. Documentation of positive clinical response (e.g., blood phenylalanine concentration less
than 600 micromol/L, 20% reduction in blood phenylalanine concentration from pre-
treatment baseline)
-AND-
b. Patient is actively on a phenylalanine-restricted diet
-AND-
© 2025 UnitedHealthcare Services Inc.
1
c. Patient is not receiving Palynziq in combination with sapropterin dihydrochloride
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Medical Necessity and supply limits may also be in place.
4. References:
1. Palynziq [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.
2. Vockley et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline.
American College of Medical Genetics and Genomics Practice Guidelines. Genetics in Medicine
2014;16 (2):188-200.
Program Prior Authorization/Notification - Palynziq (pegvaliase-pqpz)
Change Control
7/2018 New program
7/2019 Annual review with no change to coverage criteria.
7/2020 Annual review with no change to coverage criteria.
7/2021 Annual review with no change to coverage criteria. Reference updated.
7/2022 Annual review with no change to coverage criteria. Removed Brand name
Kuvan. Added state mandate disclaimer.
7/2023 Annual review with no change to coverage criteria.
7/2024 Annual review. Simplified reauthorization criteria to standard
documentation of positive clinical response language.
6/2025 Annual review with no change to coverage criteria.
© 2025 UnitedHealthcare Services Inc.
2